GERMANTOWN, Maryland and
HILDEN, Germany, October 5, 2017 /PRNewswire/ --
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today
announced the U.S. launch of QuantiFERON®-TB Gold Plus
(QFT®-Plus), the fourth generation of its leading blood
test for tuberculosis (TB) infection. QFT-Plus kits will be
available on October 9, 2017 for
diagnostic use following U.S. Food and Drug Administration approval
in June.
QFT-Plus advances the science of TB testing with innovative
antigens that measure the cell-mediated immune response
to tuberculosis infection from both CD4+ and CD8+ T cells -
providing a broader assessment of TB infection. CD8+ T cells have
been shown to play an important role in Mycobacterium
tuberculosis immunity.
Click here for the full press release
http://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-05-QFT-Plus-Launch-US?sc_lang=en
Contacts:
QIAGEN
Investor Relations
John Gilardi
e-mail: ir@QIAGEN.com
+49-2103-29-11711
Public Relations
Dr. Thomas Theuringer
e-mail: pr@QIAGEN.com
+49-2103-29-11826
SOURCE QIAGEN